Clinical Trial Update: To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of TQB3616 in combination with Fulvestrant versus placebo in combination with Fulvestrant for previously untrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• TQB3616

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HR-positive, HER2-negative Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING